Miktan Combi

Tamsulosin Hydrochloride/Dutasteride, the active ingredient in Miktan Combi, is an Alpha-1 adrenergic blocker and 5-alpha-reductase inhibitor presented as a tablet for oral use. It is indicated for the treatment of benign prostatic hyperplasia in adult male patients. The combination therapy targets both dynamic and static components of prostate enlargement, improving urinary flow and reducing symptom severity.

GNH USA supplies Miktan Combi as a licensed, GDP-compliant international pharmaceutical supplier, ensuring quality and regulatory compliance while serving hospitals, pharmacies and clinics worldwide.

Miktan Combi is used to manage conditions related to benign prostatic hyperplasia and its associated urinary symptoms. - Benign prostatic hyperplasia (BPH): reduces prostate volume and alleviates urinary obstruction. - Lower urinary tract symptoms (LUTS) due to BPH: improves urinary flow rate and decreases frequency and urgency. - Prostate enlargement: helps shrink the gland and relieve bladder outlet obstruction.

Miktan Combi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of lightheadedness, especially after standing. - Ejaculation disorders: reduced volume or retrograde ejaculation. - Decreased libido: lowered sexual desire. - Nasal congestion: stuffy or runny nose. - Diarrhea: loose stools. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Orthostatic hypotension: marked drop in blood pressure upon standing, leading to fainting. - Severe liver injury: jaundice, elevated liver enzymes, or hepatitis. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Priapism: prolonged painful erection. - Breast tenderness or enlargement.

Before prescribing Miktan Combi, clinicians should consider several precautionary measures. - Cardiovascular assessment: evaluate for history of hypotension or syncopal episodes. - Liver function monitoring: check baseline enzymes and repeat if clinically indicated. - Drug selection in elderly: start with lowest effective dose due to increased sensitivity. - Concomitant α‑blockers: avoid combining with other agents that may cause additive blood pressure lowering. - Surgery planning: discontinue the medication several weeks before prostate surgery to reduce bleeding risk. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Miktan Combi can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may enhance risk of severe hypotension. - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase dutasteride plasma levels. - Alpha‑adrenergic agonists (e.g., midodrine): antagonize tamsulosin’s effect, causing unpredictable blood pressure changes.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding tendency. - Antihypertensives: additive blood pressure lowering; monitor BP. - CYP2C9 substrates (e.g., warfarin, phenytoin): possible altered metabolism of dutasteride.